Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 31,250 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 31,250 shares of Akero Therapeutics stock in a transaction on Monday, January 27th. The stock was sold at an average price of $55.77, for a total value of $1,742,812.50. Following the transaction, the insider now directly owns 170,237 shares of the company's stock, valued at $9,494,117.49. This trade represents a 15.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Timothy Rolph also recently made the following trade(s):

• On Tuesday, December 10th, Timothy Rolph sold 4,818 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.91, for a total transaction of $148,924.38.

Akero Therapeutics Stock Performance

Shares of AKRO stock traded down $1.28 during mid-day trading on Friday, reaching $54.08. The company's stock had a trading volume of 1,380,855 shares, compared to its average volume of 1,950,830. The company's 50 day simple moving average is $30.69 and its 200-day simple moving average is $29.07. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a 12-month low of $15.32 and a 12-month high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings data on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.15). Research analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AKRO has been the subject of several recent research reports. Canaccord Genuity Group raised their price target on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. HC Wainwright upped their price objective on shares of Akero Therapeutics from $50.00 to $72.00 and gave the company a "buy" rating in a research note on Monday, January 27th. Morgan Stanley raised their target price on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 28th. Citigroup increased their price target on Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Finally, UBS Group lifted their price objective on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research report on Friday. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $75.86.

Hedge Funds Weigh In On Akero Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. purchased a new position in Akero Therapeutics in the second quarter valued at about $347,000. Renaissance Technologies LLC bought a new stake in shares of Akero Therapeutics in the second quarter worth $565,000. The Manufacturers Life Insurance Company raised its holdings in Akero Therapeutics by 26.1% in the second quarter. The Manufacturers Life Insurance Company now owns 107,172 shares of the company's stock valued at $2,514,000 after acquiring an additional 22,195 shares in the last quarter. Handelsbanken Fonder AB increased its position in shares of Akero Therapeutics by 12.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company's stock worth $574,000 after purchasing an additional 2,200 shares during the last quarter. Finally, Creative Planning acquired a new stake in shares of Akero Therapeutics in the 3rd quarter valued at about $371,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.